Can PRP’s proenzyme approach change pancreatic cancer treatment strategy? Explore what Propanc Biopharma’s data means for oncology innovation.
Find out how MIRA Pharmaceuticals aims to transform CIPN care with Ketamir-2 and why regulators and investors are watching its 2026 development milestones.
GT Biopharma’s GTB-5550 gets FDA clearance for a Phase 1 solid tumor trial. Find out how this NK cell engager could reshape B7-H3 cancer immunotherapy.
FDA grants breakthrough therapy designation to Relay Therapeutics’ zovegalisib. Find out what this changes for PI3K-mutant breast cancer treatment.
FDA clears Prelude Therapeutics’ IND for PRT12396. Discover what this mutant-selective JAK2 approach could change for MPN drug development.
Theriva’s APAO 2026 VCN-01 data reveals how viral synergy and local delivery could redefine pediatric eye cancer care.
Invivyd’s LIBERTY trial could reshape COVID prophylaxis by comparing VYD2311 antibody safety with mRNA vaccines. See what’s at stake for regulators.
FDA halts Anaphylm over human factors risks. Find out what this means for non-injectable epinephrine and future anaphylaxis treatments.
EMA backs EURneffy 1 mg for pediatric anaphylaxis in EU. Discover how needle-free adrenaline could reshape allergy emergency response today.
Tafenoquine’s retail debut via GoodRx marks a shift in malaria prevention access. Find out what this means for U.S. travel medicine strategy.